Eliem Therapeutics, Inc.
Net BuyingELYM·US·🇺🇸 US
68%buys·32%sales
293 transactions$635.0MTotal buys·44 buys
$3.5MTotal sells·21 sells
3030 insiders
Last: Dec 12, 2025
Eliem Therapeutics, Inc. is seeing coordinated insider buying. 7 insiders purchased shares in the last 30 days, with total buy volume of $5.3M. Overall insider sentiment is bullish (68% purchases).
Eliem Therapeutics, Inc. (ELYM) has recorded 293 insider operations, including 44 open-market purchases ($635.0M), 21 sales ($3.5M) and 228 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bullish (68% purchases).
Among the most active insiders are Azelby Robert (CEO), Brennan Aoife (CEO) & ALTSCHULLER Susan (CFO), with respectively 73, 56, 17 transactions.
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Advanced analytics coming soon
Price impact analysis, win rates, and predictive signals are being developed.